Core Viewpoint - Shanghai Aikebaifa Biopharmaceutical Technology Co., Ltd. (Aikebaifa) has submitted its listing application to the Hong Kong Stock Exchange, with JPMorgan and CITIC Securities acting as joint sponsors [1]. Company Overview - Aikebaifa, established in 2013, focuses on discovering and developing therapies to address medical needs in respiratory and pediatric diseases. The company has developed a pipeline of six candidate drugs targeting various stages of respiratory and pediatric diseases, including its core product Qiruisuo Wei, which is in the New Drug Application (NDA) stage for treating respiratory syncytial virus (RSV) infections [4][5]. Product Pipeline - The candidate drugs include: - Qiruisuo Wei: First-in-class drug for RSV treatment in NDA stage - AK0610: Monoclonal antibody in Phase II for RSV prevention - AK3280: Drug for idiopathic pulmonary fibrosis (IPF) in Phase II clinical stage - AK0901: ADHD drug in NDA stage - AK0705: Drug for chronic obstructive pulmonary disease (COPD) - AK0406: Drug for influenza [4][5]. Competitive Advantages - Aikebaifa claims several competitive advantages: - Leading global innovation in RSV treatment and prevention - Potential best-in-class new generation IPF drug - New generation ADHD treatment filling a critical market gap in China - Dual drug development engine with mature global business development and multi-platform R&D capabilities - Strong research and development leadership supported by notable stakeholders [5]. Financial Performance - The company reported losses for the fiscal years ending June 30, 2023, and 2024, amounting to approximately RMB 270 million and RMB 197 million, respectively. The losses for the six months ending June 30, 2024, and 2025, were approximately RMB 87.5 million and RMB 104.3 million, respectively [5][6].
爱科百发递表港交所 专注于解决呼吸系统和儿科疾病的医疗需求
Zhi Tong Cai Jing·2025-09-15 08:08